Marker Therapeutics, Inc., a clinical-stage immuno-oncology company focusing on next-generation T cell immunotherapies, announced that CEO Dr. Juan Vera will participate in a live webcast on May 28, ...
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...
In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken ...
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well ...
The project focuses on developing an innovative dual-targeting CAR-T therapy designed to attack Multiple Myeloma cells through two distinct cancer markers — BCMA (B-cell maturation antigen) and CD19.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results